Gland Pharma (NSE:GLAND) Debt-to-Revenue : 0.06 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Gland Pharma Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Gland Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹2,309 Mil. Gland Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹1,412 Mil. Gland Pharma's annualized Revenue for the quarter that ended in Mar. 2024 was ₹61,498 Mil. Gland Pharma's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 0.06.

Gland Pharma Debt-to-Revenue Historical Data

The historical data trend for Gland Pharma's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gland Pharma Debt-to-Revenue Chart

Gland Pharma Annual Data

Trend

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Debt-to-Revenue

Get a 7-Day Free Trial

0.07

Gland Pharma Quarterly Data
	Mar19	Jun19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Revenue	Get a 7-Day Free Trial															-	-	0.07	-	0.06

Competitive Comparison of Gland Pharma's Debt-to-Revenue

For the Drug Manufacturers - General subindustry, Gland Pharma's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gland Pharma's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gland Pharma's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Gland Pharma's Debt-to-Revenue falls into.

Gland Pharma Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Gland Pharma's Debt-to-Revenue for the fiscal year that ended in Mar. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(2309.47	+	1412.19)	/	56647.22
	=	0.07

Gland Pharma's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(2309.47	+	1412.19)	/	61498
	=	0.06

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.

Gland Pharma Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Gland Pharma's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Gland Pharma (NSE:GLAND) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gland Pharma Ltd (NSE:GLAND) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

543245:India

Address

Plot No. 11 and 84, TSIIC Phase: IV, Pashamylaram (V), Patancheru (M), Sangareddy District, Hyderabad, TG, IND, 502307

Website

https://www.glandpharma.com

Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, Daptomycin Injection, among others. Further, the group is involved in vast range of therapeutic categories that include Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarial, Cardiology and more - to Hormones and related Drugs, Fertility Supplements and Gnrh Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA.

Gland Pharma (NSE:GLAND) Headlines

No Headlines